OrthoPediatrics Corp.
- Open
- 19.18
- Day high
- 19.70
- Day low
- 19.04
- Prev close
- 19.13
- Volume
- 47K
- Mkt cap
- $491M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.4
- P/S
- 2.0
- Yield
- —
- Per share
- —
OrthoPediatrics Corp. (KIDS) is a Healthcare company listed on NASDAQ. The stock is down 12% over the past year.
OrthoPediatrics Corp. (KIDS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
KIDS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | $-0.38 | $-0.42 | -10.5% | $59M | +1.8% |
| Oct 28, 2025 | $-0.26 | $-0.24 | +7.7% | $61M | +3.3% |
| Mar 4, 2025 | $-0.33 | $-0.29 | +12.1% | $53M | -0.6% |
| Mar 6, 2024 | $-0.28 | $-0.23 | +17.9% | $38M | -4.5% |
| May 1, 2023 | $-0.29 | $-0.29 | +0.0% | $32M | -20.4% |
| Feb 28, 2023 | $-0.22 | $-0.32 | -45.5% | $31M | -0.0% |
| Oct 31, 2022 | $-0.19 | $-0.05 | +73.7% | $35M | -3.3% |
| Aug 3, 2022 | $-0.15 | $-0.17 | -13.3% | $33M | +1.6% |
| May 4, 2022 | $-0.30 | $-0.30 | +0.0% | $23M | +2.9% |
| Mar 2, 2022 | $-0.30 | $-0.24 | +20.0% | $25M | +0.4% |
| Nov 3, 2021 | $-0.26 | $-0.15 | +42.3% | $25M | -6.1% |
| Aug 4, 2021 | $-0.21 | $-0.11 | +47.6% | $27M | +0.0% |
KIDS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 10, 2026 | Bailey David Rdirector, officer: President and CEO | Grant | 119,140 | — |
| Jun 10, 2026 | Ruf Harolddirector | Grant | 11,436 | — |
| Jun 10, 2026 | Riccitelli Samuel Ddirector | Grant | 11,436 | — |
| Jun 10, 2026 | Hughes Bryan Wdirector | Grant | 11,436 | — |
| Jun 10, 2026 | Pelizzon David Rdirector | Grant | 11,436 | — |
| Jun 10, 2026 | Fischer Kelly Lainedirector | Grant | 11,436 | — |
| Jun 10, 2026 | Dyer George Sinclair Mitchelldirector | Grant | 11,436 | — |
| Jun 10, 2026 | Throdahl Mark Cdirector | Grant | 11,436 | — |
| Jun 10, 2026 | Infante (Reynolds) Marie Cdirector | Grant | 11,436 | — |
| Jun 10, 2026 | McDonald Jimmy Duanedirector | Grant | 11,436 | — |
| Mar 17, 2026 | Hite Freddirector, officer: COO and CFO | Sell | 12,993 | $17.25 |
| Mar 17, 2026 | Hauser Joseph Wofficer: Pres. Trauma & Def. Correction | Sell | 8,596 | $17.25 |
| Mar 17, 2026 | Hauser Joseph Wofficer: Pres. Trauma & Def. Correction | Grant | 65,700 | — |
| Mar 17, 2026 | Gerritzen Daniel Jofficer: General Counsel and Secretary | Sell | 8,614 | $17.25 |
| Mar 17, 2026 | Gerritzen Daniel Jofficer: General Counsel and Secretary | Grant | 47,380 | — |
Source: KIDS SEC Form 4 filings, latest Jun 10, 2026. For informational purposes only — not investment advice.
See the full KIDS insider & 13F page →OrthoPediatrics Corp. company profile
Overview
OrthoPediatrics Corp. (NASDAQ:KIDS) is a specialized medical device company founded in 2006 and headquartered in Warsaw, Indiana. The company went public in October 2017 and has established itself as a leading provider of orthopedic implants and devices specifically designed for children. Unlike traditional orthopedic companies that primarily focus on adult patients, OrthoPediatrics exclusively serves the pediatric orthopedic market, developing anatomically appropriate solutions for treating orthopedic conditions in children. The company has grown through both organic expansion and strategic acquisitions, including the 2023 acquisition of Boston O&P, which expanded its presence in the pediatric specialty bracing market.
Business
OrthoPediatrics operates in the pediatric orthopedic medical device industry, which represents a specialized niche within the broader orthopedic device market. The company designs, develops, and markets medical implants and devices specifically sized and engineered for children's anatomy, addressing the unique challenges of treating growing bones and smaller body structures. The company operates through three primary business segments. Trauma and Deformity products represent the largest segment, accounting for approximately 70-75% of total revenue. This segment includes products like PediLoc plates, PediPlates, cannulated screws, PediFlex nails, and various fixation systems used to treat bone fractures, limb deformities, and other traumatic injuries in children. These devices are specifically designed to accommodate the unique properties of pediatric bones, which are softer and more porous than adult bones. The Scoliosis segment generates approximately 25-30% of revenue and focuses on treating spinal deformities in children. Key products include the RESPONSE Spine systems, ApiFix Mid-C system for adolescent idiopathic scoliosis, and various growing rod systems for early onset scoliosis. Scoliosis treatment in children is particularly complex because traditional fusion procedures can limit spinal growth, requiring specialized solutions that can accommodate continued development. The Sports Medicine and Specialty Bracing segment, while smaller, includes anterior cruciate ligament reconstruction systems and the recently acquired Orthopedic Pediatric Specialty Bracing (OPSB) business through Boston O&P. The OPSB segment provides non-surgical orthotic devices and bracing solutions for various pediatric conditions, operating through a network of clinics primarily in the northeastern United States. The pediatric orthopedic market differs significantly from adult orthopedics because children's bones are still growing and developing. Standard adult-sized implants are often inappropriate for pediatric patients, creating the need for specialized devices that can accommodate growth while providing proper treatment. This market serves pediatric orthopedic surgeons, hospitals with pediatric programs, and specialized children's hospitals worldwide.
Revenue model
OrthoPediatrics generates revenue primarily through direct product sales of medical devices and implants to hospitals, surgical centers, and pediatric orthopedic surgeons. The company employs a direct sales force in the United States and works through distributors in international markets. Revenue is typically recognized when products are delivered and used in surgical procedures. The company's business model includes several key components. Set deployments represent a significant portion of the sales strategy, where OrthoPediatrics places comprehensive instrument sets and implant inventory directly in hospitals. This approach ensures surgeons have immediate access to the full range of pediatric-specific sizes and configurations needed during procedures, while also creating switching costs for hospitals. The company typically invests $15-25 million annually in new set deployments. The OPSB (Orthopedic Pediatric Specialty Bracing) business operates through a different model, providing ongoing clinical services through a network of specialized clinics. This segment generates recurring revenue through insurance reimbursements for bracing services and follow-up care, creating a more predictable revenue stream compared to the implant business. Several factors influence the company's margins and profitability. Positive margin drivers include the specialized nature of pediatric orthopedics, which commands premium pricing due to limited competition and the critical nature of proper pediatric treatment. The company's exclusive focus on pediatric patients creates expertise and relationships that are difficult for competitors to replicate. Additionally, the set deployment strategy creates customer stickiness and recurring implant sales. Margin pressures come from the significant upfront investments required for set deployments, which can impact cash flow timing. The company also faces ongoing research and development costs to maintain its product pipeline, as pediatric devices require specialized engineering and often lengthy regulatory approval processes. International expansion requires distributor margins and regulatory compliance costs in multiple jurisdictions. Healthcare reimbursement pressures and hospital cost containment initiatives can also impact pricing power, though the specialized nature of pediatric care provides some protection from these trends.
Competitive moat
OrthoPediatrics possesses a moderate to strong competitive moat based primarily on specialization and switching costs. The company's exclusive focus on pediatric orthopedics creates several defensive advantages that are difficult for competitors to replicate. The most significant moat factor is specialization expertise. Developing effective pediatric orthopedic devices requires deep understanding of growing bone physiology, child-specific anatomical considerations, and the unique challenges of treating patients whose bodies are still developing. This expertise has been built over nearly two decades and encompasses product design, clinical relationships, and regulatory knowledge specific to pediatric applications. Large orthopedic companies like Stryker or Medtronic primarily focus on the much larger adult market, making pediatric products a small, specialized segment that receives limited attention and investment. Customer switching costs provide additional protection through the set deployment strategy. Once a hospital has OrthoPediatrics instrument sets and surgeons are trained on the systems, switching to competitors requires significant retraining, new capital investments, and potential disruption to surgical workflows. Pediatric orthopedic surgeons often develop strong preferences for specific implant systems based on their experience with successful outcomes. Regulatory barriers also contribute to the moat, as FDA approval processes for pediatric medical devices can be lengthy and expensive. New entrants must invest significant time and capital to develop competitive products and navigate regulatory requirements. However, the moat has limitations. The pediatric orthopedic market is relatively small compared to adult orthopedics, which limits the absolute size of the opportunity and could make it attractive for larger competitors if growth rates justify the investment. Additionally, the company faces potential disruption from technological advances like 3D printing of custom implants or minimally invasive surgical techniques that could change treatment paradigms. The OPSB business operates in a more fragmented market with lower barriers to entry, though the clinical expertise and hospital relationships provide some protection.
Risks & safety
OrthoPediatrics presents a moderate margin of safety with solid balance sheet strength but ongoing profitability challenges. • Liquidity and Solvency: Strong cash position of $33.4 million with total current assets of $232 million against current liabilities of $37.5 million, providing a current ratio of 6.2x. Low debt levels with debt-to-equity ratio of 0.07, indicating minimal solvency risk. • Cash Flow Concerns: Negative free cash flow of -$8.4 million in Q1 2025 and -$41.3 million for full year 2024. The company expects to achieve first positive free cash flow quarter in Q4 2025 and breakeven by 2026, but execution risk remains. • Profitability Metrics: Negative EBITDA of -$10.9 million in Q1 2025, though management projects $15-17 million positive adjusted EBITDA for full year 2025. Return on equity remains negative at -3.1%. • Valuation Considerations: Trading at 1.6x book value with negative earnings making traditional P/E ratios meaningless. EV/Revenue multiple appears reasonable for a growing medical device company, but cash burn creates valuation uncertainty. • Other Factors: Revenue growth remains strong at 17% in Q1 2025, and the specialized market position provides some downside protection. However, the company's path to profitability depends on successful execution of growth initiatives and margin expansion.
Recent development
Over the past few years, OrthoPediatrics has pursued several key strategic initiatives to diversify its revenue base and accelerate growth. The most significant development was the 2023 acquisition of Boston O&P for $22 million, which brought 26 specialty bracing clinics and established the OPSB (Orthopedic Pediatric Specialty Bracing) business segment. This acquisition expanded the company's total addressable market by approximately $775 million and provided a recurring revenue stream through clinical services rather than just device sales. The company has aggressively expanded its product portfolio through both internal development and acquisitions. Recent FDA approvals include the Verteglide system, sterile PNP femur and tibia products, and the 3P pediatric plating platform. The company has also been developing advanced technologies like the 7D surgical navigation platform and the eLLi electromechanical growing rod system, which represents a significant advancement in early onset scoliosis treatment. International expansion has become a major focus, particularly in Europe where the company is working toward EU MDR (Medical Device Regulation) compliance. Management expects the first wave of EU approvals for trauma and limb deformity products, followed by scoliosis portfolio expansion. This international push is critical as the U.S. market represents approximately 78% of current revenue. The company has also invested heavily in set deployment strategies, placing comprehensive instrument sets directly in hospitals to improve surgeon access and create switching costs. Annual set deployment investments of $15-25 million have been a key driver of market share gains, though they impact near-term cash flow. Recent developments include plans to expand the OPSB clinic network to four new territories in 2025, with potential for further expansion based on early success. The company has also been developing specialized products for early onset scoliosis, representing a significant unmet medical need and potential differentiation opportunity.
KIDS company profile · for informational purposes only — not investment advice.
Track KIDS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free